Although many findings have shown that the PD-L1 expression rate of EML4-ALK fusion in NSCLC is higher than that of wild type, the poor efficacy of immunotherapy in NSCLC with EML4-ALK fusion is conflicting, and the reason to explain this phenomenon may be the significant difference in study populations and study methods. The gene discussed is CD274; the disease is non-small cell lung carcinoma.